Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-04-11
2006-04-11
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007900, C435S013000, C436S063000, C436S086000, C436S089000, C436S094000, C436S173000, C436S174000, C436S501000, C436S518000, C530S300000, C530S350000, C530S387900, C514S014800
Reexamination Certificate
active
07026129
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: WO 90/14148 (1990-11-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/07036 (1998-02-01), None
Tockman et al. “Consideration in bringing a caner biomarker to clinincal application.” Cancer Research, Suppl. vol. 52, pp. 2711s-2718s, May 1992.
Hampel et al. “Core biological marker candidates of Alzheimer's disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity.”Journal of Neural Transmission, 2004, vol. 111, pp. 247-272.
Takahashi et al., “Rapid and Sensitive Immunoassay for the Measurement of Serum S100β Using Isoform-specific Monoclonal Antibody”, Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
Richter et al., “Composition of the peptide fraction in human blood plasma: database of circulating human peptides”, Journal of Chromatography B; 726 (1999) pp. 25-35.
Jackowski George
Marshall John
Cook Lisa V.
Le Long V.
McHale & Slavin P.A.
Syn X Pharma, Inc.
LandOfFree
IG lambda biopolymer markers predictive of Alzheimers disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IG lambda biopolymer markers predictive of Alzheimers disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IG lambda biopolymer markers predictive of Alzheimers disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605559